PrimeRFP SCOUT · Federal Contract Recompete Brief

19AQMM25F14902025 - 2026 FLU vaccines — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36F79722D0178. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Oct 9, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Acquisitions - Aqm Momentum
Awarding office
Glaxosmithkline LLC
Recipient
Oct 9, 2025
PoP end
$668K
Obligated
$668K
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal
Contract number19AQMM25F1490
Also listed as19AQMM-25-F-1490
Also listed as36F79722D0178-19AQMM25F1490
AgencyAcquisitions - Aqm Momentum
Awarding officeAcquisitions - Aqm Momentum
Awarding agencyDepartment of State (DOS)
Funding agencyDepartment of State (DOS)
IncumbentGlaxosmithkline LLC
CAGE667E9
UEIFRHTPHMZMX47
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79722D0178
Place of performanceDURHAM NC
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startSep 9, 2025
PoP end (current)Oct 9, 2025
Obligated$668K
Current value$668K
Potential value$668K

2025 - 2026 FLU VACCINES is a federal award for Acquisitions - Aqm Momentum held by Glaxosmithkline LLC. Estimated value $668K ($668K obligated). Current period of performance ends Oct 9, 2025. Last award drew 1 bidder. Place of performance: DURHAM NC.

Recompete timing

Public
Past PoP end (316 days ago)

Current PoP ended Oct 9, 2025 (316 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Glaxosmithkline LLC$3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies
Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%
Open full company profile

Related awards

Same parent · incumbent
75A50125F61019
FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E
$491K
Aug 30, 2026
75A50126F61020
TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…
$493K
Oct 29, 2026
15F06724F0001366
GSK TRAVEL VACCINES
$115K
Dec 31, 2026
15F06726F0000234
GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187
$105K
Dec 31, 2026
75A50124F61014
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …
$18.4M
Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 19AQMM25F1490?

19AQMM25F1490 (2025 - 2026 FLU vaccines) is a Acquisitions - Aqm Momentum award with a potential value of $668K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 19AQMM-25-F-1490?

19AQMM-25-F-1490 is the dashed form of PIID 19AQMM25F1490 (2025 - 2026 FLU vaccines), held by Glaxosmithkline LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 19AQMM25F1490?

Acquisitions - Aqm Momentum awarded 19AQMM25F1490 to Glaxosmithkline LLC (potential $668K).

Who is the incumbent on 19AQMM25F1490?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Oct 9, 2025.

When does Glaxosmithkline LLC’s 19AQMM25F1490 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 9, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/19AQMM25F1490